Abcam ramps up in California
Cambridge UK antibody technology specialist Abcam has joined forces with California company Cell Marque Corporation in a 10-year deal set to broaden the frontiers of scientific research based on rabbit antibodies.
Abcam is a global leader in the manufacture and supply of innovative protein research tools and services; and Cell Marque provides antibodies and reagents for diagnostic immunohistochemistry.
The alliance will see Cell Marque apply its extensive IVD expertise to incorporate Abcam’s IVD IHC RabMAb primary antibodies into its portfolio and use its established distribution channels to distribute them to the global market. The agreement will give customers faster, easier access to Abcam’s high-quality antibodies.
The antibodies use Abcam’s powerful RabMAb technology offering superior binding affinity and specificity, and have been specifically developed to provide high-quality results to pathology laboratories for immunohistochemical staining of formalin-fixed paraffin embedded (FFPE) tissue.
Alan Hirzel, chief marketing officer, Abcam, said: “We are excited about the growth opportunity that this agreement provides. Part of our strategy is to work with partners that offer complementary high-quality products and who share our vision of enabling researchers to discover more.
“The agreement with Cell Marque will enable Abcam to extend its reach within the in vitro diagnostics market, with a broader range of customers able to access our in-house developed RabMAb products.”
Nora Lacey, president and CEO of Cell Marque, added: “The agreement with Abcam demonstrates Cell Marque’s ability to meet the quality and performance requirements of pathologists and will expand our offering of exceptional quality diagnostic tools.”
In a separate move, Abcam has launched an exclusive range of highly validated conjugated antibodies for use in key imaging applications including immunofluorescence, flow cytometry, and fluorescent western blotting.
Abcam’s conjugated antibodies enable scientists to easily perform multi-protein analysis. It is essential for scientists to study and image proteins in their multi-component state rather than individually, as research findings indicate that proteins rarely operate in isolation but function within multi-protein complexes.
The majority of the new antibodies are developed using Abcam’s RabMAb® technology, and are conjugated to Alexa Fluor® dyes, HRP, or biotin, combining high signal to noise ratios with high specificity. Each antibody has been produced and extensively validated by Abcam’s scientists. Performance data including images, references and customer reviews is provided with each product.